

Brief Summary of Prescribing Information for Swine

Before using Tulissin® 25 (tulathromycin injection) consult the product insert, a summary of which follows:



Antibiotic

25 mg of tulathromycin/mL
For use in swine

CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

INDICATIONS:

Swine

TULISSIN 25 Injectable Solution is indicated for the treatment of swine respiratory disease (SRD) associated with *Actinobacillus pleuropneumoniae*, *Pasteurella multocida*, *Bordetella bronchiseptica*, *Haemophilus parasuis*, and *Mycoplasma hyopneumoniae*; and for the control of SRD associated with *Actinobacillus pleuropneumoniae*, *Pasteurella multocida*, and *Mycoplasma hyopneumoniae* in groups of pigs where SRD has been diagnosed.

DOSAGE AND ADMINISTRATION

Swine

Inject intramuscularly as a single dose in the neck at a dosage of 2.5 mg/kg (1 mL/22 lb) Body Weight (BW). Do not inject more than 4 mL per injection site.

Table 1. TULISSIN 25 Swine Dosing Guide (25 mg/mL)

Animal Weight (Pounds)	Dose Volume (mL)
4	0.2
10	0.5
15	0.7
20	0.9
22	1.0
25	1.1
30	1.4
50	2.3
70	3.2
90	4.0

CONTRAINDICATIONS

The use of TULISSIN 25 Injectable Solution is contraindicated in animals previously found to be hypersensitive to the drug.

WARNINGS

FOR USE IN ANIMALS ONLY.

NOT FOR HUMAN USE.

KEEP OUT OF REACH OF CHILDREN.

NOT FOR USE IN CHICKENS OR TURKEYS.

RESIDUE WARNINGS

Swine intended for human consumption must not be slaughtered within 5 days from the last treatment.

PRECAUTIONS

Swine

The effects of Tulissin 25 Injectable Solution on porcine reproductive performance, pregnancy, and lactation have not been determined. Intramuscular injection can cause a transient local tissue reaction that may result in trim loss of edible tissue at slaughter.

ADVERSE REACTIONS

Swine

In one field study, one out of 40 pigs treated with tulathromycin injection (100 mg/mL) at 2.5 mg/kg BW exhibited mild salivation that resolved in less than four hours.

STORAGE CONDITIONS:

Store at or below 30°C (86°F). Use within 45 days of first puncture and puncture a maximum of 30 times. Consider using automatic injection equipment or a repeater syringe. When using a needle or draw-off spike larger than 16 gauge, discard any remaining product immediately after use.

Manufactured for:

Virbac AH, Inc.
P.O. Box 162059, Fort Worth, TX 76161
Made in France

Approved by FDA under ANADA # 200-668

To report suspected adverse drug events, for technical assistance or to obtain a copy of the Safety Data Sheet (SDS), contact Virbac AH, Inc. at 1-800-338-3659 or us.virbac.com. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or <http://www.fda.gov/reportanimalae>.

TAKE TIME



OBSERVE LABEL DIRECTIONS

©2021 Virbac Corporation. All Rights Reserved.
TULISSIN is a registered trademark of Virbac S.A.

Rev. 06/21

Brief Summary of Prescribing Information for Swine

Before using Tulissin® 100 (tulathromycin injection) consult the product insert, a summary of which follows:



Antibiotic

100 mg of tulathromycin/mL
For use in swine.

CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

INDICATIONS:

Swine

TULISSIN 100 Injectable Solution is indicated for the treatment of swine respiratory disease (SRD) associated with *Actinobacillus pleuropneumoniae*, *Pasteurella multocida*, *Bordetella bronchiseptica*, *Haemophilus parasuis*, and *Mycoplasma hyopneumoniae*; and for the control of SRD associated with *Actinobacillus pleuropneumoniae*, *Pasteurella multocida*, and *Mycoplasma hyopneumoniae* in groups of pigs where SRD has been diagnosed.

DOSAGE AND ADMINISTRATION

Inject intramuscularly as a single dose in the neck at a dosage of 2.5 mg/kg (0.25 mL/22 lb) BW. Do not inject more than 2.5 mL per injection site.

Table 1. TULISSIN 100 Swine Dosing Guide. (refer to Table 2 on product insert)

Animal Weight (Pounds)	Dose Volume (mL)
15	0.2
30	0.3
50	0.6
70	0.8
90	1.0
110	1.3
130	1.5
150	1.7
170	1.9
190	2.2
210	2.4
230	2.6
250	2.8
270	3.1
290	3.3

CONTRAINDICATIONS

The use of TULISSIN 100 Injectable Solution is contraindicated in animals previously found to be hypersensitive to the drug.

WARNINGS

FOR USE IN ANIMALS ONLY.

NOT FOR HUMAN USE.

KEEP OUT OF REACH OF CHILDREN.

NOT FOR USE IN CHICKENS OR TURKEYS.

RESIDUE WARNINGS

Swine intended for human consumption must not be slaughtered within 5 days from the last treatment.

PRECAUTIONS

Swine

The effects of Tulissin 100 on porcine reproductive performance, pregnancy, and lactation have not been determined. Intramuscular injection can cause a transient local tissue reaction that may result in trim loss of edible tissue at slaughter.

ADVERSE REACTIONS

Swine

In one field study, one out of 40 pigs treated with tulathromycin injection at 2.5 mg/kg BW exhibited mild salivation that resolved in less than four hours.

STORAGE CONDITIONS:

Store at or below 30°C (86°F). Use within 45 days of first puncture and puncture a maximum of 20 times. Consider using automatic injection equipment or repeater syringe. When using a needle or draw-off spike larger than 16 gauge, discard any remaining product immediately after use.

Manufactured for:

Virbac AH, Inc.
P.O. Box 162059, Fort Worth, TX 76161
Made in France

Approved by FDA under ANADA # 200-669

To report suspected adverse drug events, for technical assistance or to obtain a copy of the Safety Data Sheet (SDS), contact Virbac AH, Inc. at 1-800-338-3659 or us.virbac.com. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or <http://www.fda.gov/reportanimalae>.

TAKE TIME



OBSERVE LABEL DIRECTIONS

©2021 Virbac Corporation. All Rights Reserved.
TULISSIN is a registered trademark of Virbac S.A.

Rev. 10/21

Tulissin[®]-25- (tulathromycin injection)



Protect Your Investment

If you trust your herd with tulathromycin, then you need TULISSIN[®] 25 Injectable Solution.

Why TULISSIN® 25 (tulathromycin injection) Should Be Your Go-To Solution for SRD



TULISSIN® 25 (tulathromycin injection) and TULISSIN® 100 (tulathromycin injection) IMPORTANT SAFETY INFORMATION FOR SWINE
Ensure a preslaughter withdrawal time of five (5) days in swine. Do not use in animals known to be hypersensitive to the product.

Tulathromycin, a first choice therapy¹ for treating Swine Respiratory Disease (SRD):


- **Goes to work in minutes**²
- Concentrates in the **most susceptible areas** of the respiratory system
- Provides **nine days** of lung activity to treat and control SRD³
- **Convenient dosages** with availability of TULISSIN® 100 (tulathromycin injection) for use in large pigs with the same preslaughter withdrawal time of five days

TULISSIN® 25 Injectable Solution is formulated for weaned pigs to allow for accurate dosing.



TULISSIN 25 mg/mL
For swine: 1 mL/22 lb. BW

TULISSIN® 100 Injectable Solution is available for use in large pigs. Note: Effects on swine reproduction have not been determined.




TULISSIN 100 mg/mL
For swine: 1 mL/90 lb. BW

50 Years of Results Lands Stateside

Virbac brings its global livestock health experience, reputation for quality and commitment to animal health to the U.S. TULISSIN® 25 Injectable Solution is a tulathromycin option that helps preserve herd health and productivity while delivering a return on your investment.

Number of Virbac Injectable Antibiotics for Livestock by Area



Packaging Sizes

	50 mL	100 mL	250 mL	500 mL
Tulissin® 25 - (tulathromycin injection)		✓	✓	
Tulissin® 100 - (tulathromycin injection)	✓	✓	✓	✓



SCAN THE QR CODE TO SEE THE SHOCK-ABSORBING SHELL IN ACTION.



¹ CEESA data, Q2 2021, injectable antibiotics brands used in swine segment

² Villarino N, Brown SA, Martin-Jimenez T. Understanding the pharmacokinetics of tulathromycin: a pulmonary perspective. *J Vet Pharmacol Ther.* 2014;37(3):211-221.

³ Waag TA, Bradford JR, Lucas MJ, et al. Duration of effectiveness of tulathromycin injectable solution in an *Actinobacillus pleuropneumoniae* respiratory-disease challenge model in swine. *J Swine Health Prod.* 2008;16(3):126-130.